trending Market Intelligence /marketintelligence/en/news-insights/trending/VXOTBx0LCQ5uGdxTjrhzdw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biogen Q4'16 earnings slashed by license agreement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biogen Q4'16 earnings slashed by license agreement

Biogen Inc. reported a 22% year-over-year decrease in its fourth-quarter 2016 GAAP income.

The result, $649.2 million, or $2.99 per share, compares to $831.6 million, or $3.77 per share, in the 2015 fourth quarter and reflects a license agreement that resulted in a $455 million pre-tax charge during the closing months of 2016.

Biogen recently secured the rights to use Forward Pharma A/S' method for treating multiple sclerosis for $1.25 billion in cash. Biogen will make the payment and possibly up to 10% or 20% in royalties on the sale of Tecfidera, which uses Forward's patent protected method for multiple sclerosis.

The $455 million charge represents the portion of the payment attributable to the sales of Tecfidera during the April 2014 to Dec. 31, 2016, period.

Excluding the charge, Biogen recorded $1.09 billion, or $5.04 per share, in non-GAAP net income for the 2016 fourth quarter. This would compare to $995 million, or $4.50 per share, for the corresponding quarter of 2015.

The result beats the S&P Capital IQ consensus normalized EPS estimate of $4.96.

Biogen recorded $2.87 billion in revenues during the fourth quarter of 2016, bringing the year's total up by 6% to $11.45 billion when compared to 2015.

The company's full-year 2016 GAAP net income was also up to $3.70 billion, or $16.93 per share, from $3.55 billion, or $15.34 per share, in 2015.

Biogen recorded $4.42 billion, or $20.22 per share, in full-year 2016 non-GAAP income, which would compare to the $3.93 billion, or $17.01 per share, recorded in 2015.

Full-year non-GAAP income also beats the S&P Capital IQ consensus normalized EPS estimate of $20.17.

Biogen will target between $18 and $18.80 in GAAP and $20.45 and $21.25 in non-GAAP income during 2017.